Compare SKYX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | KZIA |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.3M | 154.9M |
| IPO Year | 2014 | 2002 |
| Metric | SKYX | KZIA |
|---|---|---|
| Price | $1.18 | $13.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.00 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.9M | 163.5K |
| Earning Date | 05-13-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $25.12 | N/A |
| Revenue Next Year | $24.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.95 | $4.86 |
| 52 Week High | $3.29 | $17.40 |
| Indicator | SKYX | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 47.64 |
| Support Level | $1.00 | $5.25 |
| Resistance Level | $1.29 | $14.75 |
| Average True Range (ATR) | 0.10 | 0.99 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 65.16 | 33.72 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.